Cancer immunotherapy could be one of the hottest sectors in which to invest, according to a top dog at global financial conglomerate UBS.
This thinking is certainly in line with the bullish biotech market in recent years, though it’s refreshing to hear a Wall Street heavy hitter speaking optimistically about the field – particularly since biopharma’s come under fire of late.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“This emerging science offers the potential for attractive returns,” Mark Haefele, the company’s global chief investment officer told Business Insider. “The market for cancer treatments is expanding rapidly as populations age, and governments, insurers and individuals are spending more on treatments that can extend life.”
He cited the fact that spending per cancer patient has risen about 60 percent between 2010 and 2014, and that early immunotherapies are costing upwards of $100,000 – facts that make these treatments attractive to investors.
“We believe some of these drugs will hit the market in the coming two years with multi-billion dollar sales potential,” Hafaele said. “Companies highly exposed to successful immunotherapy drugs are likely to offer above-GDP earnings growth, elevated returns on capital, and growing dividends.”
[Photo from Flickr user Wellcome Images]
